{"title":"The significance of chirality in contemporary drug discovery-a mini review","link":"http://pubs.rsc.org/en/Content/ArticleLanding/2024/RA/D4RA05694A","date":null,"content":"<div><p><img src=\"/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D4RA05694A\" /></p></div><div><i><b>RSC Adv.</b></i>, 2024, <b>14</b>,33429-33448<br /><b>DOI</b>: 10.1039/D4RA05694A, Review Article</div><div><img alt=\"Open Access\" src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/open_access_blue.png\" /> Open Access</div><div><a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\"> <img src=\"http://sod-a.rsc-cdn.org/pubs.rsc-uat.org/content/NewImages/CCBY-NC.png\" alt=\"Creative Commons Licence\" /></a>Â  This article is licensed under a <a href=\"http://creativecommons.org/licenses/by-nc/3.0/\" target=\"_blank\">Creative Commons Attribution-NonCommercial 3.0 Unported Licence.</a></div><div>Narmatha Senkuttuvan, Boopathi Komarasamy, Rajavenkatesh Krishnamoorthy, Shuvajyoti Sarkar, Sivasankaran Dhanasekaran, Parthiban Anaikutti<br />In this review, we wish to compile examples of chiral medicines approved by the FDA in the years 2022 and 2023 with an emphasis on their synthesis along with information on chiral induction as well enantiomeric excess.<br />The content of this RSS Feed (c) The Royal Society of Chemistry</div>","author":"","siteTitle":"RSC - RSC Adv. latest articles","siteHash":"da3e282678330308414c63a405ade89dd3738fcce2936ca8a2fe3a6d7e967d99","entryHash":"9e26821e7262d1a433af236e765b90441d040ca7888f2b4aee1766132f42a829","category":"Environment"}